Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 2007

View Archived Issues

Pramipexole shows potential in treatment-resistant depression

Recent patents describe new therapeutic agents for diabetes

Protease-mediated CXCR1 cleavage increases infection risk in cystic fibrosis lung disease

LPA1: a novel therapeutic target for idiopathic pulmonary fibrosis

New antiinfective agents disclosed in recent patent literature

Basilea files Canadian New Drug Submission for alitretinoin for chronic hand eczema

Progen's phase III study of PI-88 for HCC open for recruitment

Diamyd files IND with FDA for phase III clinical trial of Diamyd for type 1 diabetes

Lundbeck and Paion expand license agreement for desmoteplase

Medivir and Presidio amend MIV-310 license agreement

Phase I trial commences for Cougar Biotechnology's CB-3304

AVI BioPharma starts dosing in Duchenne muscular dystrophy trial

Pharming requests re-examination of CHMP opinion for Rhucin

Eisai commences cash tender offer for outstanding MGI shares

Cubist acquires Illumigen Biosciences

Fresenius applies for marketing authorization of Removab for malignant ascites

Preliminary phase II results reported for Sinovac's pandemic influenza vaccine

Cell Therapeutics completes Zevalin's acquisition for U.S. sales and marketing

CytRx initiates phase IIb trial with arimoclomol for the treatment of ALS

Galvus obtains positive opinion regarding E.U. prescribing information changes

Endocyte and R&D-Biopharmaceuticals enter tubulysin chemo agent agreement

Collegium reports results for its abuse deterrent sustained release opioid study

Immtech's pafuramidine program on clinical hold

Antisense provides update on ATL-1102 phase IIa multiple sclerosis trial

PharmaMar's Yondelis completes requirements for launch in Spain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...